Relationship between Cardiopulmonary, Mitochondrial and Autonomic Nervous System Function Improvement after an Individualised Activity Programme upon Chronic Fatigue Syndrome Patients. — CFSMEATLAS
Relationship between Cardiopulmonary, Mitochondrial and Autonomic Nervous System Function Improvement after an Individualised Activity Programme upon Chronic Fatigue Syndrome Patients.
Kujawski, Sławomir, Cossington, Jo, Słomko, Joanna et al. · Journal of clinical medicine · 2021 · DOI
Quick Summary
This study tested whether a personalized activity program could help ME/CFS patients feel less tired and function better. Thirty-four patients followed a 16-week program tailored to their individual abilities. After the program, patients reported significant improvements in fatigue, and blood tests showed improvements in mitochondrial markers (Mfn1 and Mfn2)—the energy-producing components of cells. However, about half of the patients found exercise difficult to tolerate.
Why It Matters
This study addresses growing concerns about exercise-based interventions in ME/CFS by examining whether individualized programs can improve fatigue without harm. The finding that mitochondrial markers improve alongside fatigue reduction provides biological support for activity-based approaches. Understanding which patients tolerate activity well and which do not is critical for developing safer, more personalized treatment strategies.
Observed Findings
Fatigue scores (CFQ, FSS, FIS) decreased significantly after 16 weeks of the Individualised Activity Program
VO2peak correlated with Mfn1 increase in response to the program (p=0.03)
VO2 at anaerobic threshold correlated with autonomic nervous system response to Head-Up Tilt Test (p=0.03)
Inferred Conclusions
Individualised Activity Programs can reduce fatigue and improve functional capacity in ME/CFS patients
Improvements in mitochondrial function (Mfn1/Mfn2) may be a biological mechanism linking activity to fatigue improvement
Autonomic nervous system function improves in response to activity-based intervention
Individualized activity approaches warrant further investigation despite tolerance challenges in some patients
Remaining Questions
Why did 51% of patients not tolerate exercise, and can we identify biomarkers or clinical features that predict who will benefit versus who will experience harm?
Does the improvement in mitochondrial markers drive fatigue reduction, or is the relationship more complex and multidirectional?
What This Study Does Not Prove
This study does not prove that exercise is universally safe or effective for ME/CFS patients, since 51% did not tolerate it well. The study cannot determine whether improvements in mitochondrial markers directly cause fatigue reduction or are simply correlated with activity participation. Without a control group receiving no intervention, the study cannot rule out placebo effects or natural disease fluctuation as contributing factors.
How do outcomes compare with a control group receiving standard care or placebo, and do improvements persist beyond the 16-week intervention period?
What specific components of the individualized activity program are most therapeutic, and how should intensity and progression be titrated for different patient subgroups?